[go: up one dir, main page]

SI3237618T1 - RNA inducirana supresija huntingtin gena - Google Patents

RNA inducirana supresija huntingtin gena

Info

Publication number
SI3237618T1
SI3237618T1 SI201530791T SI201530791T SI3237618T1 SI 3237618 T1 SI3237618 T1 SI 3237618T1 SI 201530791 T SI201530791 T SI 201530791T SI 201530791 T SI201530791 T SI 201530791T SI 3237618 T1 SI3237618 T1 SI 3237618T1
Authority
SI
Slovenia
Prior art keywords
gene suppression
huntingtin gene
rnai induced
induced huntingtin
rnai
Prior art date
Application number
SI201530791T
Other languages
English (en)
Inventor
Pavlina Stefanova Konstantinova
Jana Miniarikova
Original Assignee
Uniqure Ip B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniqure Ip B.V. filed Critical Uniqure Ip B.V.
Publication of SI3237618T1 publication Critical patent/SI3237618T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201530791T 2014-12-24 2015-12-23 RNA inducirana supresija huntingtin gena SI3237618T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14200308 2014-12-24
PCT/EP2015/081157 WO2016102664A1 (en) 2014-12-24 2015-12-23 Rnai induced huntingtin gene suppression
EP15817385.6A EP3237618B1 (en) 2014-12-24 2015-12-23 Rnai induced huntingtin gene suppression

Publications (1)

Publication Number Publication Date
SI3237618T1 true SI3237618T1 (sl) 2019-09-30

Family

ID=52282540

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530791T SI3237618T1 (sl) 2014-12-24 2015-12-23 RNA inducirana supresija huntingtin gena

Country Status (25)

Country Link
US (4) US10174321B2 (sl)
EP (2) EP3540063A1 (sl)
JP (2) JP6839094B2 (sl)
KR (1) KR102636633B1 (sl)
CN (1) CN108064292B (sl)
AU (1) AU2015370903B2 (sl)
CA (1) CA2971920C (sl)
CO (1) CO2017007335A2 (sl)
CY (1) CY1121733T1 (sl)
DK (1) DK3237618T3 (sl)
EA (1) EA037696B1 (sl)
ES (1) ES2732023T3 (sl)
HK (1) HK1246344B (sl)
HR (1) HRP20190992T1 (sl)
HU (1) HUE043842T2 (sl)
IL (1) IL252990B (sl)
LT (1) LT3237618T (sl)
MX (1) MX381121B (sl)
PL (1) PL3237618T3 (sl)
PT (1) PT3237618T (sl)
RS (1) RS58862B1 (sl)
SI (1) SI3237618T1 (sl)
SM (1) SMT201900347T1 (sl)
TR (1) TR201908969T4 (sl)
WO (1) WO2016102664A1 (sl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 官能化核酸の合成のための方法
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
KR101850319B1 (ko) 2012-07-13 2018-04-20 웨이브 라이프 사이언시스 리미티드 비대칭 보조 그룹
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
HK1244299A1 (zh) 2014-11-14 2018-08-03 Voyager Therapeutics, Inc. 治療肌萎縮側索硬化(als)的組合物和方法
WO2016102664A1 (en) * 2014-12-24 2016-06-30 Uniqure Ip B.V. Rnai induced huntingtin gene suppression
US10450563B2 (en) 2015-02-10 2019-10-22 Genzyme Corporation Variant RNAi
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
US10457940B2 (en) * 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
BR112019025740A2 (pt) 2017-06-05 2020-06-23 Ptc Therapeutics, Inc. Compostos para tratar a doença de huntington
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MY205041A (en) 2017-09-22 2024-09-29 Genzyme Corp Variant rnai
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
CN108384803A (zh) * 2017-12-19 2018-08-10 上海百力格生物技术有限公司 一种用于miRNA干扰载体构建筛选特异对照的质粒及其构建方法
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
MA51938B1 (fr) * 2018-05-15 2022-10-31 Univ Washington Compositions et procédés pour réduire les anomalies d'épissage et traiter des troubles de dominance arn
WO2019222413A1 (en) * 2018-05-15 2019-11-21 University Of Massachusetts Modified aav constructs and uses thereof
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP7565218B2 (ja) 2018-07-02 2024-10-10 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症および脊髄に関連する障害の治療
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ O-メチルリッチ完全安定化オリゴヌクレオチド
CA3112007A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
CA3120177A1 (en) * 2018-11-19 2020-05-28 Uniqure Ip B.V. Method and means to deliver mirna to target cells
JP2022507283A (ja) 2018-11-19 2022-01-18 ユニキュアー アイピー ビー.ブイ. 脊髄小脳失調症3型の治療のためのアタキシン-3のrnai誘導低減
CA3119721A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
CN113302302A (zh) * 2019-01-09 2021-08-24 科英布拉大学 双链rna及其用途
AU2020207935A1 (en) 2019-01-18 2021-08-26 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
WO2021053018A1 (en) 2019-09-16 2021-03-25 Uniqure Ip B.V. Targeting misspliced transcripts in genetic disorders
CN114650822A (zh) 2019-11-01 2022-06-21 诺华股份有限公司 剪接调节子用于减慢亨廷顿氏病进展的治疗的用途
KR20220094213A (ko) * 2019-11-01 2022-07-05 알닐람 파마슈티칼스 인코포레이티드 헌팅틴 (HTT) iRNA 제제 조성물 및 이의 사용 방법
WO2021204872A1 (en) * 2020-04-07 2021-10-14 Uniqure Ip B.V. Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
US20220090069A1 (en) * 2020-08-03 2022-03-24 University Of Massachusetts Oligonucleotides for htt-1a modulation
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
AU2022246786A1 (en) 2021-03-29 2023-10-05 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
CN115141848A (zh) * 2021-03-30 2022-10-04 南京大学 一种用于治疗亨廷顿病的rna递送系统
EP4359525A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Gene constructs for silencing alpha-synuclein and uses thereof
JP2025503910A (ja) * 2022-01-27 2025-02-06 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 神経疾患を処置するための組成物
EP4508213A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of apoe
EP4508214A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of c9orf72
US20250230437A1 (en) 2022-04-12 2025-07-17 Uniqure Biopharma B.V. Novel systems for nucleic acid regulation
WO2023198663A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of snca
WO2024218204A1 (en) 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
WO2025051805A1 (en) 2023-09-04 2025-03-13 Uniqure Biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles
WO2025078598A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Novel nucleic acid regulation of huntingtin gene
WO2025078602A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Nucleic acid regulation of msh3 in repeat expansion disorders
WO2025078606A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Further novel systems for nucleic acid regulation
WO2025106739A1 (en) * 2023-11-14 2025-05-22 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of htt expression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526893C (en) 2003-05-14 2010-10-26 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
EP1735443A2 (en) 2004-04-14 2006-12-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN101287837B (zh) 2005-10-20 2015-03-18 尤尼克尔生物制药股份有限公司 昆虫细胞中生产的改进的aav载体
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
CA2662704A1 (en) 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
US20090036395A1 (en) * 2007-04-26 2009-02-05 Davidson Beverly L Rna interference suppression of neurodegenerative diseases and methods of use thereof
PT2164967E (pt) 2007-05-31 2015-10-27 Univ Iowa Res Found Redução da toxicidade não dirigida do arn de interferência
PL3093345T3 (pl) 2007-07-26 2020-03-31 Uniqure Ip B.V. Wektory bakulowirusowe zawierające powtórzone sekwencje kodujące o zróżnicowanej preferencji kodonów
EP2250256B1 (en) 2008-02-19 2017-08-02 uniQure IP B.V. Optimisation of expression of parvoviral rep and cap proteins in insect cells
EP2411505A4 (en) * 2009-03-26 2013-01-30 Univ California MESENCHYMAL STEM CELLS FOR PRODUCING HEMDERING RNA FOR SICKNESS MODIFICATION
HRP20181423T1 (hr) * 2009-05-02 2018-11-30 Genzyme Corporation Genska terapija za neurodegenerativne poremećaje
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
EP2561078B1 (en) * 2010-04-23 2018-09-19 Cold Spring Harbor Laboratory NOVEL STRUCTURALLY DESIGNED shRNAs
EP2583692A4 (en) * 2010-06-18 2014-11-26 Lsip Llc HEMMER OF THE EXPRESSION OF DOMINANT ALLELES
KR101961347B1 (ko) 2011-09-08 2019-03-25 유니큐어 아이피 비.브이. Aav 제조물로부터 오염 바이러스의 제거
CN103224556B (zh) * 2013-01-31 2015-04-15 清华大学 亨廷顿舞蹈症的靶位蛋白质及其编码基因和应用
WO2016102664A1 (en) * 2014-12-24 2016-06-30 Uniqure Ip B.V. Rnai induced huntingtin gene suppression

Also Published As

Publication number Publication date
PL3237618T3 (pl) 2019-09-30
EA037696B1 (ru) 2021-05-12
ES2732023T3 (es) 2019-11-20
KR102636633B1 (ko) 2024-02-13
HUE043842T2 (hu) 2019-09-30
CN108064292A (zh) 2018-05-22
US20170355989A1 (en) 2017-12-14
US20200339992A1 (en) 2020-10-29
CO2017007335A2 (es) 2018-01-05
HK1246344B (en) 2020-01-10
IL252990B (en) 2021-09-30
RS58862B1 (sr) 2019-07-31
HUE043842T4 (hu) 2019-08-28
EP3237618A1 (en) 2017-11-01
PT3237618T (pt) 2019-07-04
LT3237618T (lt) 2019-07-10
CN108064292B (zh) 2021-05-04
SMT201900347T1 (it) 2019-07-11
WO2016102664A1 (en) 2016-06-30
MX381121B (es) 2025-03-12
JP2021000136A (ja) 2021-01-07
DK3237618T3 (da) 2019-06-24
JP2018502601A (ja) 2018-02-01
JP6839094B2 (ja) 2021-03-03
EP3540063A1 (en) 2019-09-18
US10767180B2 (en) 2020-09-08
CY1121733T1 (el) 2020-07-31
US20230119344A1 (en) 2023-04-20
US10174321B2 (en) 2019-01-08
BR112017013573A2 (pt) 2018-03-06
TR201908969T4 (tr) 2019-07-22
EP3237618B1 (en) 2019-05-22
US11371044B2 (en) 2022-06-28
AU2015370903B2 (en) 2021-06-17
US20190144860A1 (en) 2019-05-16
CA2971920C (en) 2024-05-07
MX2017008500A (es) 2018-02-01
KR20170120572A (ko) 2017-10-31
EA201791417A1 (ru) 2017-12-29
CA2971920A1 (en) 2016-06-30
HRP20190992T1 (hr) 2019-09-20
AU2015370903A1 (en) 2017-07-20
IL252990A0 (en) 2017-08-31
NZ733296A (en) 2021-10-29

Similar Documents

Publication Publication Date Title
IL252990A0 (en) Rnai induces Huntington gene repression
IL253893A0 (en) variant of rnai
IL250448B (en) Modified double helix RNA materials
IL247624A0 (en) Intentional healing
ZA201607100B (en) Frequency response
SG11201606379UA (en) Aptamer construct
GB201517285D0 (en) Stabilizer arrangement
IL249254B (en) Gene expression system
GB201408823D0 (en) Demulsifiers
IL246956A0 (en) targeted therapies
IL257500A (en) Altered cullin1 gene
GB201621449D0 (en) Frequency-domain denoising
IL248812A0 (en) Very effective stabilizer
SG11201702844VA (en) Photobioreactor
GB2547614B (en) Stabilizer
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB201608944D0 (en) Gene Tharapy
AU5592P (en) Lanmichigan Mandevilla boliviensis x sanderi
GB201410599D0 (en) Sensitizers
IL230329A0 (en) croc sponge
GB201403353D0 (en) Novel oligonucleotides
GB201403087D0 (en) Novel oligonucleotides
GB201407865D0 (en) Nucleases